Zobrazeno 1 - 10
of 47
pro vyhledávání: ''
Autor:
Eunice Y. Lau, Man Tong, Katherine Po Sin Chung, Terence K. Lee, Stephanie Ma, Rainbow Wing Hei Leung, Etienne H. Mok, Irene Oi-Lin Ng, Martina Mang Leng Lei, Q Zhao, Vincent W. Keng, Carmen Oi Ning Leung, Hoi Wing Leung, Cong Ma
Publikováno v:
Cancer Research. 81:3229-3240
The survival benefit derived from sorafenib treatment for patients with hepatocellular carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) is a possible way to reverse drug resistance, however, inhibitors that spec
Autor:
Pelin Gülizar Ersan, Hong Pei, Joel Linden, Sara Serra, Kim Phan, Qiping Zhao, Caglar Cekic, Renee Clift, H. Michael Shepard, Lei Huang, Michael J. LaBarre, Mertkaya Aras, Christopher D. Thanos, Lin Wang, Ozgur Sahin, Jessica Cowell, Xiaoming Li, Silvia Deaglio, Luz Marina Londoño, Ozge Saatci
Publikováno v:
Cancer Research. 81:3319-3332
Extracellular adenosine in tumors can suppress immune responses and promote tumor growth. Adenosine deaminase 2 (ADA2) converts adenosine into inosine. The role of ADA2 in cancer and whether it can target adenosine for cancer therapy has not been inv
Autor:
Samuel Achilefu, Michael H. Ross, Jingyu Xiang, Kristin A. Kwakwa, Elizabeth Cordell, Alison K. Esser, Vivek Sharma, Kristen Pagliai, Francesca Fontana, Jennifer L. Davis, Deborah J. Veis, Suzanne J. Bakewell, Xinming Su, Gregory M. Lanza, Katherine N. Weilbaecher, Gregory C. Fox, Christopher G. Maher, Jothilingam Sivapackiam, James A. J. Fitzpatrick, Yalin Xu, Ha X. Dang, Sheila A. Stewart
Publikováno v:
Mol Cancer Ther
Breast cancer bone metastases are common and incurable. Tumoral integrin β3 (β3) expression is induced through interaction with the bone microenvironment. Although β3 is known to promote bone colonization, its functional role during therapy of est
Autor:
Hsin-Fang Tu, Ming-Shyue Lee, Geen-Dong Chang, Santiago Ramón-Maiques, Chia-Chi Ku, Der-Yen Lee, Chao-Chi Ho, Hsin-Ying Lin, Ching-Tai Lee, Francisco Del Caño-Ochoa, Chun-Jung Ko, Ya-Hui Chuang, I-Chun Chen, Shao-Wei Lan, Hsin-Hsien Lin, Cheng-Fan Lee
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
13 páginas, 7 figuras
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced C
Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune checkpoint blockade (ICB) therapies show no additional effect. This raises questions regarding whether EGFR-TKIs attenuate ICB-enhanced C
Autor:
Guohua Zhang, James Z. Zhu, Min Li, Yan Zuo, Jeffrey A. Frost, Zicheng Zhang, Yi-Ping Li, Thomas K. Sin
Publikováno v:
Cancer Res
Cancer-associated cachexia, characterized by muscle wasting, is a lethal metabolic syndrome without defined etiology or established treatment. We previously found that p300 mediates cancer-induced muscle wasting by activating C/EBPβ, which then upre
Autor:
Manmeet S. Ahluwalia, Sarah Johnson, Tyler J. Alban, Charlie Androjna, Balint Otvos, Justin D. Lathia, Defne Bayik, Alireza M. Mohammadi, Erin E. Mulkearns-Hubert, Tomas Radivoyevitch, Matthew M. Grabowski, Michael A. Vogelbaum, Anja Rabljenovic, Peter E. Fecci, Gene H. Barnett
Publikováno v:
Clin Cancer Res
Purpose: Glioblastoma (GBM) immunotherapy clinical trials are generally initiated after standard-of-care treatment—including surgical resection, perioperative high-dose steroid therapy, chemotherapy, and radiation treatment—has either begun or fa
Autor:
Nikhil C. Munshi, Daisuke Tsuchimoto, Mei Yin, Allison J. Janocha, Yi Hu, Hua Fang, Shan Yan, Thomas LaFramboise, Li Xue, Alex Mejia-Garcia, Chen Li, Chun Yang, Jennifer S. Yu, Jianhong Lin, Kenneth C. Anderson, Chuanfeng Fang, Yusaku Nakabeppu, Qing Y. Zheng, Tania Amorim, Xin Qi, Leal Herlitz, Faiz Anwer, Jenny Lin, Jack Khouri, Mohsin Maqbool, Ariel Kwart, Xiaofeng Jiang, Jianjun Zhao
Publikováno v:
Cancer Res
Cisplatin chemotherapy is standard care for many cancers but is toxic to the kidneys. How this toxicity occurs is uncertain. In this study, we identified apurinic/apyrimidinic endonuclease 2 (APE2) as a critical molecule upregulated in the proximal t
Autor:
Zahid H. Siddik, Bangxing Hong, Uksha Saini, David E. Cohn, Anil K. Sood, Guangsheng Pei, Guangan He, Zhongming Zhao, Yuanqing Yan, Karuppaiyah Selvendiran, Valerie Chapa, Balveen Kaur, Ji Young Yoo, Puneet Modgil
Publikováno v:
Clin Cancer Res
Purpose:Here we investigated the impact of oncolytic herpes simplex virus (HSV) treatment on cisplatin sensitivity of platinum-resistant ovarian cancer, and the impact of the combination on immunotherapy.Experimental Design:Therapeutic efficacy of th
Autor:
Xiaoxia Yang, Steven Fletcher, Noriko Yanaba, John S. Allen, Julie Ritchey, Julie O'Neal, Grace Cui, Ravi Vij, Mark A. Fiala, Anne H. Schmieder-Atteberry, Kathleen Simons, Francesca Fontana, Michael J. Scott, John F. DiPersio, Dipanjan Pan, Michael P. Rettig, Gregory M. Lanza
Publikováno v:
Clin Cancer Res
Purpose: In multiple myeloma, drug-resistant cells underlie relapse or progression following chemotherapy. Cell adhesion–mediated drug resistance (CAM-DR) is an established mechanism used by myeloma cells (MMC) to survive chemotherapy and its marke
Autor:
Carsten Sticht, Carolin Mogler, Olga Ermakova, Fabian Rose, Stefan Thomann, Eduard Ryschich, Carolina De La Torre, Daniel Kazdal, Kai Breuhahn, Claudia R. Ball, Norbert Gretz, Stephanie Roessler, Simone Marquard, Sarah Fritzsche, Peter Schirmacher, S Weiler, Teng Wei, Eugen Rempel, Hanno Glimm, Marcell Tóth
Publikováno v:
Cancer Research. 80:5502-5514
The oncogene yes-associated protein (YAP) controls liver tumor initiation and progression via cell extrinsic functions by creating a tumor-supporting environment in conjunction with cell autonomous mechanisms. However, how YAP controls organization o